For example, Takada et al, in 89 patients with advanced NSCLC receiving anti-PD-1 therapy, found that pre-treatment SUVmax ≥ 11.16 was significantly associated with higher response rate (41.3%) compared to those with an SUVmax < 11.16 (11.6%) [17]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.